

Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 2, 2025

Alexa Fluor(R) 700 anti-human CD16

RRID:AB_2278418

Type: Antibody

Proper Citation

(BioLegend Cat# 302026, RRID:AB_2278418)

Antibody Information

URL: http://antibodyregistry.org/AB_2278418

Proper Citation: (BioLegend Cat# 302026, RRID:AB_2278418)

Target Antigen: CD16

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Alexa Fluor(R) 700 anti-human CD16

Description: This monoclonal targets CD16

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone 3G8

Antibody ID: AB_2278418

Vendor: BioLegend

Catalog Number: 302026

Alternative Catalog Numbers: 302025

Record Creation Time: 20231110T044337+0000

Record Last Update: 20241115T060639+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 700 anti-human CD16.

No alerts have been found for Alexa Fluor(R) 700 anti-human CD16.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Audran R, et al. (2024) Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study. *Scientific reports*, 14(1), 12872.

Tang F, et al. (2023) A pan-cancer single-cell panorama of human natural killer cells. *Cell*, 186(19), 4235.

Li H, et al. (2023) Abundant binary promoter switches in lineage-determining transcription factors indicate a digital component of cell fate determination. *Cell reports*, 42(11), 113454.

O'Donnell KL, et al. (2023) Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine. *EBioMedicine*, 89, 104463.

Chen G, et al. (2023) Derived myeloid lineage induced pluripotent stem as a platform to study human C-C chemokine receptor type 5³² homozygotes. *iScience*, 26(11), 108331.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. *Cell*, 185(5), 916.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell*, 185(3), 493.

Koutsakos M, et al. (2021) Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. *Cell reports. Medicine*, 2(3), 100208.

Portillo AL, et al. (2021) Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. *iScience*, 24(6), 102619.

Rao S, et al. (2021) Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. *Cell stem cell*, 28(5), 833.

Hearnden R, et al. (2021) Isolation of stromal vascular fraction cell suspensions from mouse

and human adipose tissues for downstream applications. STAR protocols, 2(2), 100422.

Wieland A, et al. (2021) Defining HPV-specific B cell responses in patients with head and neck cancer. Nature, 597(7875), 274.

Vanoni G, et al. (2021) Human primed ILCPs support endothelial activation through NF- κ B signaling. eLife, 10.

Cytlak U, et al. (2020) Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans. Immunity, 53(2), 353.

Pham TNQ, et al. (2019) Flt3L-Mediated Expansion of Plasmacytoid Dendritic Cells Suppresses HIV Infection in Humanized Mice. Cell reports, 29(9), 2770.

de Jonge K, et al. (2019) Circulating CD56^{bright} NK cells inversely correlate with survival of melanoma patients. Scientific reports, 9(1), 4487.